ARTICLES BY THIS AUTHOR
- 9/23/2021
CDC director overrules agency's advisors on COVID-19 boosters
Centers for Disease Control and Prevention director Rochelle Walensky overruled her agency advisory panel by recommending COVID-19 boosters for people at risk of the coronavirus because of their jobs. - 9/22/2021
Incyte wins FDA nod for Opzelura
Opzelura is the first and only topical formulation of a Janus kinase inhibitor approved in the United States. - 9/22/2021
Glenmark gets FDA green light for generic Evoclin
Evoclin Foam had a market value of approximately $12 million for the 12 months endedJuly 2021, according to IQVIA. - 9/22/2021
FDA OKs Pfizer's COVID-19 vaccine booster for older adults, people at high risk
The Food and Drug Administration granted an emergency use authorization for the booster in individuals age 65 years old and older, and individuals age 18 to 64 years old within certain high-risk groups. - 9/21/2021
Scynexis debuts Brexafemme
Brexafemme is the first and only oral non-azole prescription medication approved by the FDA to treat vaginal yeast infection. - 9/21/2021
Par intros generic Chantix
Chantix had a market value of approximately $1 billion for the 12 months ended June 30, according to IQVIA. - 9/20/2021
Pfizer, BioNTech Phase 2/3 trial data show COVID-19 vaccine is safe in 5 to 11 year olds
The companies plan to submit these data to the Food and Drug Administration, European Medicines Agency and other regulatory agencies around the world as soon as possible. - 9/20/2021
AAM report: Generic savings totaled $338B in 2020
Biosimilar drugs saved $7.9 billion dollars in 2020 alone, more than tripling the $2.5 billion saved in 2019, according to the latest report from the Association for Accessible Medicines. - 9/20/2021
Camber debuts generic Bystolic
Camber's nebivolol tablets provide a generic treatment for patients with hypertension. - 9/19/2021
Cipla obtains FDA nod for generic Durezol
Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA.